Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A OTT

Showing results (541-550 of 667) with videos related to

Pageof 67
Sort By:
JAMA|March 12, 1997
Apolipoprotein E epsilon4 and the risk of dementia with stroke. A population-based investigationA J Slooter, M X Tang, C M van Duijn, et al.
Pediatric Diabetes|February 10, 2019
Prevalence of celiac disease in a large cohort of young patients with type 1 diabetesMarcia Puñales, Marilia Dornelles Bastos, Ana Regina L Ramos, et al.
Neurology|September 12, 2000
The alpha2-macroglobulin gene in AD: a population-based study and meta-analysisM N Koster, B Dermaut, M Cruts, et al.
Cancer Immunology Research|April 5, 2017
Diagnostic Comparison of CT Scans and Colonoscopy for Immune-Related Colitis in Ipilimumab-Treated Advanced Melanoma PatientsMarlene Garcia-Neuer, Melina E Marmarelis, Sushrut R Jangi, et al.
Journal for Immunotherapy of Cancer|August 29, 2024
Nivolumab maintenance improves overall survival of patients with advanced melanoma who experience severe immune-related adverse events on nivolumab plus ipilimumabAnna K Maloney, Anita Giobbie-Hurder, Nikita Katukota, et al.
Journal of Immunotherapy and Precision Oncology|June 6, 2022
Impact of COVID-19 on Patients with Cancer Receiving Immune Checkpoint InhibitorsAi-Tram N Bui, Kevin Tyan, Anita Giobbie-Hurder, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 1, 2014
Phase I/II study of the antibody-drug conjugate glembatumumab vedotin in patients with advanced melanomaPatrick A Ott, Omid Hamid, Anna C Pavlick, et al.
JCO Oncology Practice|May 14, 2020
Safety of Immune Checkpoint Inhibitors in Patients With Pre-Existing Inflammatory Bowel Disease and Microscopic ColitisShilpa Grover, Alex B Ruan, Padmavathi Srivoleti, et al.
Journal for Immunotherapy of Cancer|July 24, 2021
CX-072 (pacmilimab), a Probody PD-L1 inhibitor, in combination with ipilimumab in patients with advanced solid tumors (PROCLAIM-CX-072): a first-in-human, dose-finding studyRachel E Sanborn, Omid Hamid, Elisabeth Ge de Vries, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|April 15, 2026
Brief Communication: Personalized Circulating Tumor DNA as a Predictor of Pathologic Response in Neoadjuvant Treatment of Resectable MelanomaJustine V Cohen, Mofei Liu, Grace Rogers, et al.
Pageof 67

Showing results (541-550 of 667) with videos related to

Sort By:
Pageof 67
JAMA|March 12, 1997
Apolipoprotein E epsilon4 and the risk of dementia with stroke. A population-based investigationA J Slooter, M X Tang, C M van Duijn, et al.
Pediatric Diabetes|February 10, 2019
Prevalence of celiac disease in a large cohort of young patients with type 1 diabetesMarcia Puñales, Marilia Dornelles Bastos, Ana Regina L Ramos, et al.
Neurology|September 12, 2000
The alpha2-macroglobulin gene in AD: a population-based study and meta-analysisM N Koster, B Dermaut, M Cruts, et al.
Cancer Immunology Research|April 5, 2017
Diagnostic Comparison of CT Scans and Colonoscopy for Immune-Related Colitis in Ipilimumab-Treated Advanced Melanoma PatientsMarlene Garcia-Neuer, Melina E Marmarelis, Sushrut R Jangi, et al.
Journal for Immunotherapy of Cancer|August 29, 2024
Nivolumab maintenance improves overall survival of patients with advanced melanoma who experience severe immune-related adverse events on nivolumab plus ipilimumabAnna K Maloney, Anita Giobbie-Hurder, Nikita Katukota, et al.
Journal of Immunotherapy and Precision Oncology|June 6, 2022
Impact of COVID-19 on Patients with Cancer Receiving Immune Checkpoint InhibitorsAi-Tram N Bui, Kevin Tyan, Anita Giobbie-Hurder, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 1, 2014
Phase I/II study of the antibody-drug conjugate glembatumumab vedotin in patients with advanced melanomaPatrick A Ott, Omid Hamid, Anna C Pavlick, et al.
JCO Oncology Practice|May 14, 2020
Safety of Immune Checkpoint Inhibitors in Patients With Pre-Existing Inflammatory Bowel Disease and Microscopic ColitisShilpa Grover, Alex B Ruan, Padmavathi Srivoleti, et al.
Journal for Immunotherapy of Cancer|July 24, 2021
CX-072 (pacmilimab), a Probody PD-L1 inhibitor, in combination with ipilimumab in patients with advanced solid tumors (PROCLAIM-CX-072): a first-in-human, dose-finding studyRachel E Sanborn, Omid Hamid, Elisabeth Ge de Vries, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|April 15, 2026
Brief Communication: Personalized Circulating Tumor DNA as a Predictor of Pathologic Response in Neoadjuvant Treatment of Resectable MelanomaJustine V Cohen, Mofei Liu, Grace Rogers, et al.
Pageof 67